Disco Pharmaceuticals

Disco Pharmaceuticals is a private, pre-clinical stage biotech based in Berlin, Germany, pioneering a novel approach to oncology drug discovery through comprehensive mapping of the cancer cell surfaceome. The company has secured a €36 million seed financing round and is led by a seasoned team with deep experience in oncology, company building, and business development. Its core technology aims to identify previously inaccessible protein targets and communities to enable the development of highly specific antibody therapeutics, positioning it to address significant gaps in targeted cancer therapy.

Proprietary cell surfaceome discovery platform that maps all proteins and protein communities on the cancer cell surface to identify novel, high-confidence targets for antibody-based therapeutics.

Disco competes in the broad field of oncology target discovery, which includes genomics-focused firms, proteomics platforms, and large pharma internal R&D. Its specific focus on surface protein communities differentiates it from transcriptomic or whole-cell proteomic approaches. Success hinges on proving its targets are superior in yielding specific, effective antibodies compared to those identified by competitors.